SETD2 and cancer: Here, we report using the online analytical tools of two major cancer genetic databases, The Cancer Genome Atlas (TCGA) and Genomics of Drug Sensitivity in Cancer (GDSC) to identify a novel promising compound for the selective inhibition of ccRCC with VHL and SETD2 mutations, and provide clues for the interactions between those common mutations in kidney cancer.